Skip to main content
Erschienen in: Clinical and Translational Oncology 4/2015

01.04.2015 | Research Article

A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer

verfasst von: S. Hernández-Prieto, A. Romera, M. Ferrer, J. L. Subiza, J. A. López-Asenjo, J. R. Jarabo, A. M. Gómez, Elena M. Molina, J. Puente, J. L. González-Larriba, F. Hernando, B. Pérez-Villamil, E. Díaz-Rubio, J. Sanz-Ortega

Erschienen in: Clinical and Translational Oncology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To identify a novel system for scoring intratumoral immune response that can improve prognosis and therapy decisions in early stage non-small cell lung cancer (NSCLC).

Methods/patients

Eighty-four completely resected stage I/II NSCLC without adjuvant therapy were classified by expression profiling using whole genome microarrays. An external cohort of 162 tumors was used to validate the results. Immune cells present in tumor microenvironment were evaluated semiquantitatively by CD20, CD79, CD3, CD8, CD4 and CD57 immunostaining. Univariate and multivariate analyses of variables associated with recurrence-free survival were performed.

Results

Initial molecular classification identified three clusters, one with significantly better RFS. A reduced two-subgroup classification and a 50-gene predictor were built and validated in an external dataset: high and low risk of recurrence patients (HR = 3.44; p = 0.001). Analysis of the predictor´s genes showed that the vast majority were related to a B/plasma cell immune response overexpressed in the low-risk subgroup. The predictor includes genes coding for unique B lineage-specific genes, functional elements or other genes that, although non-restricted to this lineage, have strong influence on B-cell homeostasis. Immunostains confirmed increased B-cells in the low-risk subgroup. Gene signature (p < 0.0001) and CD20 (p < 0.05) were predictors for RFS, while CD79 and K-RAS mutations showed a tendency.

Conclusions

Favorable prognosis in completely resected NSCLC is determined by a B-cell-mediated immune response. It can be differently scored by a 50-gene expression profile or by CD20 immunostaining. That prognosis information not reflected by traditional classifications may become a new tool for determining individualized adjuvant therapies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.CrossRefPubMed Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.CrossRefPubMed
2.
Zurück zum Zitat Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, et al. The IASLC Lung cancer staging project: proposals regarding the relevance of TNM in the pathologic staging of NSCLC in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4(9):1049–59.CrossRefPubMed Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, et al. The IASLC Lung cancer staging project: proposals regarding the relevance of TNM in the pathologic staging of NSCLC in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4(9):1049–59.CrossRefPubMed
3.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A et al. eds.: AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 253–704. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A et al. eds.: AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 253–704.
4.
Zurück zum Zitat Agulló-Ortuño MT, López-Ríos F, Paz-Ares L. Lung cancer genomic signatures. J Thorac Oncol. 2010;5(10):1673–91.CrossRefPubMed Agulló-Ortuño MT, López-Ríos F, Paz-Ares L. Lung cancer genomic signatures. J Thorac Oncol. 2010;5(10):1673–91.CrossRefPubMed
5.
Zurück zum Zitat Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 2006;24:1679–88.CrossRefPubMed Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 2006;24:1679–88.CrossRefPubMed
6.
Zurück zum Zitat Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol. 2008;26(6):877–83.CrossRefPubMed Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol. 2008;26(6):877–83.CrossRefPubMed
7.
Zurück zum Zitat Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected NSCLC. J Clin Oncol. 2010;28(29):4417–24.CrossRefPubMedCentralPubMed Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected NSCLC. J Clin Oncol. 2010;28(29):4417–24.CrossRefPubMedCentralPubMed
8.
Zurück zum Zitat Lu Y, Lemon W, Liu P-Y, Yi Y, Morrison C, Yang P, et al. A gene expression signature predicts survival of patients with stage I NSCLC. PLoS Med. 2006;3(12):e467.CrossRefPubMedCentralPubMed Lu Y, Lemon W, Liu P-Y, Yi Y, Morrison C, Yang P, et al. A gene expression signature predicts survival of patients with stage I NSCLC. PLoS Med. 2006;3(12):e467.CrossRefPubMedCentralPubMed
9.
Zurück zum Zitat Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, et al. An immune response enriched 72-gene prognostic profile for early-stage NSCLC. Clin Cancer Res. 2009;15(1):284–90.CrossRefPubMed Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, et al. An immune response enriched 72-gene prognostic profile for early-stage NSCLC. Clin Cancer Res. 2009;15(1):284–90.CrossRefPubMed
10.
Zurück zum Zitat Zhu CQ, Pintilie M, John T, Strumpf D, Shepherd FA, Der SD, et al. Understanding prognostic gene expression signatures in lung cancer. Clin Lung Cancer. 2009;10(5):331–40.CrossRefPubMed Zhu CQ, Pintilie M, John T, Strumpf D, Shepherd FA, Der SD, et al. Understanding prognostic gene expression signatures in lung cancer. Clin Lung Cancer. 2009;10(5):331–40.CrossRefPubMed
11.
Zurück zum Zitat Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, et al. Three-gene prognostic classifier for early-stage NSCLC. J Clin Oncol. 2007;25:5562–9.CrossRefPubMed Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, et al. Three-gene prognostic classifier for early-stage NSCLC. J Clin Oncol. 2007;25:5562–9.CrossRefPubMed
12.
Zurück zum Zitat Neumann J, Feuerhake F, Kayser G, Wiech T, Aumann K, Passlick B, et al. Gene expression profiles of lung adenocarcinoma linked to histopathological grading and survival but not to EGF-R status: a microarray study. BMC Cancer. 2010;10:77.CrossRefPubMedCentralPubMed Neumann J, Feuerhake F, Kayser G, Wiech T, Aumann K, Passlick B, et al. Gene expression profiles of lung adenocarcinoma linked to histopathological grading and survival but not to EGF-R status: a microarray study. BMC Cancer. 2010;10:77.CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegmanet P et al. Gene expression-based classification of NSCLC and survival prediction. PloS One 2010; 5(4): e10312. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegmanet P et al. Gene expression-based classification of NSCLC and survival prediction. PloS One 2010; 5(4): e10312.
14.
Zurück zum Zitat Bryant CM, Albertus DL, Kim S, Chen G, Brambilla C, Guedj M et al. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS One 2010;22; 5(7):e11712. Bryant CM, Albertus DL, Kim S, Chen G, Brambilla C, Guedj M et al. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS One 2010;22; 5(7):e11712.
15.
Zurück zum Zitat Wan YW, Sabbagh E, Raese R, Qian Y, Luo D, Denvir J et al. Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction. PLoS One 2010;17;5(8):e12222. Wan YW, Sabbagh E, Raese R, Qian Y, Luo D, Denvir J et al. Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction. PLoS One 2010;17;5(8):e12222.
16.
Zurück zum Zitat Zhu CQ, Strumpf D, Li CY, Li Q, Liu N, Der S, et al. Prognostic gene expression signature for SCC of lung. Clin Cancer Res. 2010;16:5038.CrossRefPubMed Zhu CQ, Strumpf D, Li CY, Li Q, Liu N, Der S, et al. Prognostic gene expression signature for SCC of lung. Clin Cancer Res. 2010;16:5038.CrossRefPubMed
17.
Zurück zum Zitat Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, et al. A practical molecular assay to predict survival in resected non-squamous, NSCLC: development and international validation studies. Lancet. 2012;379:823–32.CrossRefPubMedCentralPubMed Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, et al. A practical molecular assay to predict survival in resected non-squamous, NSCLC: development and international validation studies. Lancet. 2012;379:823–32.CrossRefPubMedCentralPubMed
18.
Zurück zum Zitat Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, Lopez Campos G, Calles A, Sanz-Ortega J, et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer. 2012;12:260.CrossRefPubMedCentralPubMed Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, Lopez Campos G, Calles A, Sanz-Ortega J, et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer. 2012;12:260.CrossRefPubMedCentralPubMed
19.
Zurück zum Zitat Benito M, Parker J, Du Q, Wu J, Xiang D, Perou CM, et al. Adjustment of systematic microarray data bases. Bioinformatics. 2003;20(1):105–14.CrossRef Benito M, Parker J, Du Q, Wu J, Xiang D, Perou CM, et al. Adjustment of systematic microarray data bases. Bioinformatics. 2003;20(1):105–14.CrossRef
20.
Zurück zum Zitat Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA. 2002;99(10):6567–72.CrossRefPubMedCentralPubMed Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA. 2002;99(10):6567–72.CrossRefPubMedCentralPubMed
21.
Zurück zum Zitat Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005;92:131–135. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005;92:131–135.
22.
Zurück zum Zitat Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst. 2010;102:464–74.CrossRefPubMedCentralPubMed Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst. 2010;102:464–74.CrossRefPubMedCentralPubMed
23.
Zurück zum Zitat Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst. 2007;99(2):147–57.CrossRefPubMed Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst. 2007;99(2):147–57.CrossRefPubMed
24.
Zurück zum Zitat Perez-Andres M, Paiva B, Nieto WG, Caraux J, Schmitz CA, Almeida J, et al. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom. 2010;78B(Suppl. 1):S47–60.CrossRef Perez-Andres M, Paiva B, Nieto WG, Caraux J, Schmitz CA, Almeida J, et al. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom. 2010;78B(Suppl. 1):S47–60.CrossRef
25.
Zurück zum Zitat Tangye SG, Good KL. Human IgM+ CD27+ B cells: memory B cells or “memory” B cells? J Immunol. 2007;179(1):13–9.CrossRefPubMed Tangye SG, Good KL. Human IgM+ CD27+ B cells: memory B cells or “memory” B cells? J Immunol. 2007;179(1):13–9.CrossRefPubMed
26.
Zurück zum Zitat White E. The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. Genes Dev. 2003;17(15):1813–6.CrossRefPubMed White E. The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. Genes Dev. 2003;17(15):1813–6.CrossRefPubMed
27.
Zurück zum Zitat Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 2011;25(7):1182–8. Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 2011;25(7):1182–8.
28.
Zurück zum Zitat Trinidad EM, Ballesteros M, Zuloaga J, Zapata A, Alonso-Colmenar LM. An impaired transendothelial migration potential of chronic lymphocytic leukemia (CLL) cells can be linked to ephrin-A4 expression. Blood. 2009;114(24):5081–90.CrossRefPubMed Trinidad EM, Ballesteros M, Zuloaga J, Zapata A, Alonso-Colmenar LM. An impaired transendothelial migration potential of chronic lymphocytic leukemia (CLL) cells can be linked to ephrin-A4 expression. Blood. 2009;114(24):5081–90.CrossRefPubMed
29.
Zurück zum Zitat Shapiro MJ, Nguyen CT, Aghajanian H, Zhang W, Shapiro VS. Negative regulation of TCR signaling by linker for activation of X cells via phosphotyrosine-dependent and -independent mechanisms. J Immunology. 2008;181:7055–61.CrossRef Shapiro MJ, Nguyen CT, Aghajanian H, Zhang W, Shapiro VS. Negative regulation of TCR signaling by linker for activation of X cells via phosphotyrosine-dependent and -independent mechanisms. J Immunology. 2008;181:7055–61.CrossRef
30.
Zurück zum Zitat Zikos AD, Donnenberg RJ, Landreneau JD, Luketich JD, Donnenberg VS. Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in NSCLC. Cancer Immunol Immunother. 2011;60:819–27.CrossRefPubMedCentralPubMed Zikos AD, Donnenberg RJ, Landreneau JD, Luketich JD, Donnenberg VS. Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in NSCLC. Cancer Immunol Immunother. 2011;60:819–27.CrossRefPubMedCentralPubMed
31.
Zurück zum Zitat Hagn M, Sontheimer K, Dahlke K, Brueggemann S, Kaltenmeier C, Beyer T, et al. Human B cells differentiate into granzyme B-secreting cytotoxic B lymphocytes upon incomplete T-cell help. Immunol Cell Biol. 2012;90(4):457–67.CrossRefPubMed Hagn M, Sontheimer K, Dahlke K, Brueggemann S, Kaltenmeier C, Beyer T, et al. Human B cells differentiate into granzyme B-secreting cytotoxic B lymphocytes upon incomplete T-cell help. Immunol Cell Biol. 2012;90(4):457–67.CrossRefPubMed
32.
Zurück zum Zitat Chen H-Y, Yu S-L, Chen C-H, Chang GC, Chen CY, Yuan A, et al. A five gene signature and clinical outcome in NSCLC. N Engl J Med. 2007;356:11–20.CrossRefPubMed Chen H-Y, Yu S-L, Chen C-H, Chang GC, Chen CY, Yuan A, et al. A five gene signature and clinical outcome in NSCLC. N Engl J Med. 2007;356:11–20.CrossRefPubMed
33.
Zurück zum Zitat Mahabeleshwar GH, Das R, Kundu GC. Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of EGFR/extracellular signal regulated kinase pathways. J BiolChem. 2004;279:9733–42. Mahabeleshwar GH, Das R, Kundu GC. Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of EGFR/extracellular signal regulated kinase pathways. J BiolChem. 2004;279:9733–42.
34.
Zurück zum Zitat Majolini MB, D’Elios MM, Galieni P, Boncristiano F, Lauria G, Del Prete JL, et al. Expression of the T-cell-specific tyrosine kinase lck in normal B-1 cells and in chronic lymphocytic leukemia B cells. Blood. 1998;91:3390–6.PubMed Majolini MB, D’Elios MM, Galieni P, Boncristiano F, Lauria G, Del Prete JL, et al. Expression of the T-cell-specific tyrosine kinase lck in normal B-1 cells and in chronic lymphocytic leukemia B cells. Blood. 1998;91:3390–6.PubMed
35.
Zurück zum Zitat Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat. 2012;131(3):871–80.CrossRefPubMedCentralPubMed Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat. 2012;131(3):871–80.CrossRefPubMedCentralPubMed
36.
Zurück zum Zitat Coronella JA, Telleman P, Kingsbury GA, Truong TD, Hays S, Junghans RP, et al. Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res. 2001;61(21):7889–99.PubMed Coronella JA, Telleman P, Kingsbury GA, Truong TD, Hays S, Junghans RP, et al. Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res. 2001;61(21):7889–99.PubMed
37.
Zurück zum Zitat Kotlan B, Simsa P, Teillaud JL, Fridman WH, Toth J, McKnight M, et al. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol. 2005;175(4):2278–85.CrossRefPubMed Kotlan B, Simsa P, Teillaud JL, Fridman WH, Toth J, McKnight M, et al. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol. 2005;175(4):2278–85.CrossRefPubMed
38.
Zurück zum Zitat Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012;10:1–4.CrossRefPubMedCentralPubMed Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012;10:1–4.CrossRefPubMedCentralPubMed
39.
Zurück zum Zitat Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, et al. Prognostic immune markers in NSCLC. Clin Cancer Res. 2011;17(16):5247–56.CrossRefPubMed Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, et al. Prognostic immune markers in NSCLC. Clin Cancer Res. 2011;17(16):5247–56.CrossRefPubMed
40.
Zurück zum Zitat Hernando F, Sanz J, Jarabo JR, et al. A new genetic signature defining two prognostic groups among patients with completely resected early non-small cell lung cancer. J Thor Oncol. 2012;7(6):S59. Hernando F, Sanz J, Jarabo JR, et al. A new genetic signature defining two prognostic groups among patients with completely resected early non-small cell lung cancer. J Thor Oncol. 2012;7(6):S59.
41.
Zurück zum Zitat Sanz J, Hernandez S, Hernando F, Larriba JLG, Puente J, Ferrer M, et al. An intratumoral B-cell immune response determines favorable prognosis for early stage lung cancer and can be assessed by different immunoscores. Modern Pathol. 2013;26:466A. Sanz J, Hernandez S, Hernando F, Larriba JLG, Puente J, Ferrer M, et al. An intratumoral B-cell immune response determines favorable prognosis for early stage lung cancer and can be assessed by different immunoscores. Modern Pathol. 2013;26:466A.
Metadaten
Titel
A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer
verfasst von
S. Hernández-Prieto
A. Romera
M. Ferrer
J. L. Subiza
J. A. López-Asenjo
J. R. Jarabo
A. M. Gómez
Elena M. Molina
J. Puente
J. L. González-Larriba
F. Hernando
B. Pérez-Villamil
E. Díaz-Rubio
J. Sanz-Ortega
Publikationsdatum
01.04.2015
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 4/2015
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1235-1

Weitere Artikel der Ausgabe 4/2015

Clinical and Translational Oncology 4/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.